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By analyzing the functional role of adenosine receptor heteromers, we review a series of 
new concepts that should modify our classical views of neurotransmission in the central 
nervous system (CNS). Neurotransmitter receptors cannot be considered as single 
functional units anymore. Heteromerization of neurotransmitter receptors confers 
functional entities that possess different biochemical characteristics with respect to the 
individual components of the heteromer. Some of these characteristics can be used as a 
“biochemical fingerprint” to identify neurotransmitter receptor heteromers in the CNS. 
This is exemplified by changes in binding characteristics that are dependent on 
coactivation of the receptor units of different adenosine receptor heteromers. 
Neurotransmitter receptor heteromers can act as “processors” of computations that 
modulate cell signaling, sometimes critically involved in the control of pre- and 
postsynaptic neurotransmission. For instance, the adenosine A1-A2A receptor heteromer 
acts as a concentration-dependent switch that controls striatal glutamatergic 
neurotransmission. Neurotransmitter receptor heteromers play a particularly important 
integrative role in the “local module” (the minimal portion of one or more neurons and/or 
one or more glial cells that operates as an independent integrative unit), where they act 
as processors mediating computations that convey information from diverse volume-
transmitted signals. For instance, the adenosine A2A-dopamine D2 receptor heteromers 
work as integrators of two different neurotransmitters in the striatal spine module. 
KEYWORDS: receptor heteromers, adenosine receptors, dopamine receptors, metabotropic 
glutamate receptors, local module, striatum 
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ADENOSINE RECEPTOR HETEROMERS AS PROCESSORS OF COMPUTATIONS 
THAT MODULATE CELL SIGNALING 
In the present review, we adopt the broad definition of “neurotransmitter” by Snyder and Ferris[1], i.e., a 
molecule, released by neurons or glia, which physiologically influences the electrochemical state of 
adjacent cells. This definition allows the inclusion of the term “neuromodulator”, often used to describe 
adenosine. Adenosine plays a very important modulatory role in many brain processes and in brain 
function in general. In the brain, adenosine acts mainly by stimulating two subtypes of G protein-coupled 
receptors (GPCRs): adenosine A1 and A2A receptors[2]. It is becoming evident that the modulatory role of 
adenosine involves the ability of adenosine receptors to heteromerize with many different partners, such 
as dopamine and glutamate receptors (see below). Neurotransmitter receptor heteromers are functional 
entities with distinctive biochemical properties different from those of the individual components of the 
heteromer. These biochemical characteristics include changes in ligand binding characteristics and 
signaling[3,4,5,6]. A receptor unit in the heteromer can display several biochemical properties, which can 
be simply dependent on the presence of the other unit, i.e., just as a consequence of the heteromerization, 
or on costimulation of the two (or more) receptor units in the heteromer. In case of dependence on 
costimulation, the neurotransmitter receptor heteromer acts as a “processor” of computations that 
modulate cell signaling. Thus, the quantitative or qualitative aspects of the signaling generated by 
stimulation of either receptor unit in the heteromer are different from those obtained during coactivation. 
This implies a processing of information at the membrane level of the signals impinging on the 
heteromer. Importantly, the biochemical characteristics of the receptor heteromer, which can be 
demonstrated in an artificial cell system, can constitute a “biochemical fingerprint” that allows its 
identification in the central nervous system. 
The changes in binding characteristics that are dependent on coactivation of the receptor units of the 
receptor heteromer are a common property of neurotransmitter receptor heteromers and are also known as 
“intramembrane receptor-receptor interactions”[5]. The term “intramembrane receptor-receptor 
interaction” implies an intermolecular cross-talk between both receptor units in the heteromer at the 
membrane level, without intervention of signaling pathways[5]. In some cases, stimulation of one 
receptor unit decreases, while in other cases increases, the affinity of the other receptor unit for 
endogenous or exogenous ligand binding. Intramembrane receptor-receptor interactions can be 
unidirectional or reciprocal, with only one receptor unit or both receptor units of the heteromer being able 
to modulate the binding characteristics of the other receptor unit, respectively. In the A2A-A1 and the A2A-
dopamine D2 receptor heteromers, there is a unidirectional antagonistic intramembrane interaction. Thus, 
stimulation of A2A receptors decreases the affinity of the other receptor units in the heteromer (A1 and D2 
receptors) for their respective agonists (see below). The A1-A2A receptor heteromer processes information 
carried by the same neurotransmitter (see below). On the other hand, the A2A-D2 receptor heteromer 
integrates signals from two different neurotransmitter systems, allowing adenosine to control the effects 
of dopaminergic neurotransmission antagonistically (see below).  
Among the changes in signaling, changes in G protein coupling are another common characteristic of 
neurotransmitter receptor heteromers[3,4,5,6]. In several receptor heteromers, such as opioid or dopamine 
receptor heteromers[7,8], the receptor units in the heteromer couple to G proteins other than those usually 
associated with the individually expressed receptors. An interesting example in relation to adenosine 
receptor heteromers is the recently described A2A-cannabinoid CB1 receptor heteromer[9]. The CB1 
receptor signals through coupling to Gi proteins, but in the A2A-CB1 receptor heteromer, the CB1 receptor 
does not couple to Gi protein unless there is coactivation of the A2A receptor[9]. These interactions in the 
A2A-CB1 receptor heteromer can have important implications for striatal function. Thus, it has been found 
that A2A and CB1 receptors coimmunoprecipitate from extracts of rat striatum, where they colocalize in 
fibrillar structures (nerve terminals or dendritic processes)[9]. Recent results suggest that striatal A2A-CB1 
receptor heteromers mediate the motor-depressant effects of cannabinoids[9]. Finally, receptor 
heteromerization creates an optimal frame for a tight cross-talk between the receptor units at the level of 
signaling, such as the strong and selective synergistic interactions between A2A and the metabotropic 
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glutamate mGlu5 receptor in the A2A-mGlu5 receptor heteromer at the adenylyl-cyclase and MAPK levels 
(see below). 
THE ADENOSINE A1-A2A RECEPTOR HETEROMER: A CONCENTRATION-
DEPENDENT SWITCH THAT CONTROLS STRIATAL GLUTAMATERGIC 
NEUROTRANSMISSION 
In some cases, neurotransmitter receptor heteromers can act as processors of computations that modulate 
signaling which is critically involved in pre- or postsynaptic neurotransmission. This is exemplified by 
analyzing the function of the striatal A1-A2A receptor heteromer. By means of coimmunoprecipitation and 
BRET techniques, we demonstrated the existence of A1-A2A receptor heteromers in cotransfected human 
embryonic kidney (HEK) cells[10]. We then demonstrated the existence of an intermolecular cross-talk, 
an intramembrane receptor-receptor interaction, in the A1-A2A receptor heteromer in cotransfected HEK 
cells, by means of radioligand binding techniques[10]. In cells only transfected with A1 receptors, 
competitive-inhibition experiments with the radiolabeled A1 receptor agonist [3H]R-PIA and the A2A 
receptor agonist CGS 21680 showed that CGS 21680 displaces A1 receptor binding only at high 
concentrations, when it loses its selectivity for A2A receptors. On the other hand, in cells cotransfected 
with A1 and A2A receptors (but not in mixtures of cells cotransfected with either A1 or A2A receptors), low 
concentrations of CGS 21680 also counteract A1 receptor binding. This shows the existence of an 
intramembrane interaction in the A1-A2A heteromer, by which stimulation of A2A receptor decreases the 
affinity of A1 receptor for agonist binding. We could then use this biochemical characteristic of the 
heteromer as a biochemical fingerprint and identify the A1-A2A receptor heteromer in the brain. In fact, 
the same results were obtained when we performed the same kind of competitive inhibition experiments 
in membrane preparations from rat striatum[10]. This demonstrates the existence of A1-A2A receptor 
heteromers in the striatum. It also shows that an important part of the A1 receptors in the striatum are 
forming heteromers with A2A receptors, otherwise the intramembrane A1-A2A receptor interaction would 
not be detected. 
We then wanted to know about the localization and functional relevance of the intramembrane 
interaction in the A1-A2A receptor heteromer. In previous studies using the in vivo microdialysis technique 
in freely moving rats, we found that either perfusion with the A2A receptor agonist CGS 21680 or the A1 
receptor antagonist CPT in the ventral striatum (in the shell of the nucleus accumbens) induced a dose-
dependent increase in glutamate release. The effect was counteracted by an A2A receptor antagonist 
(MSX-3) in both cases[11]. These results suggested that in the striatum, A1 and A2A receptors could be 
colocalized in glutamatergic terminals, where they would exert opposite effects on the modulation of 
glutamate release. This was confirmed by electron microscopy experiments, labeling A1 receptors with 
immunoperoxidase and A2A receptors with immunogold. Interestingly, presynaptic A1 and A2A receptors 
were mostly found inside the synapse[10]. Thus, they are in a position to modulate adenosine generated 
by synaptically released ATP, which is most probably coreleased with glutamate and converted to 
adenosine by ectonucleotidases (see below). Furthermore, immunocytochemical experiments in striatal 
nerve terminal preparations showed that the majority of glutamatergic nerve terminals contain both A1 
and A2A receptors[10].  
So, how does this heteromer work? Why do we have two receptor subtypes of the same 
neurotransmitter so closely interacting in the glutamatergic terminals? In preparations of striatal nerve 
terminals, stimulation of the A1 receptor with the A1 receptor agonist CPA, decreases potassium-induced 
glutamate release and stimulation of A2A receptors with CGS 21680 potentiates glutamate release[10]. 
Importantly, when both A1 and A2A receptors are stimulated, there is also potentiation of glutamate 
release and, in the same kind of preparation, low concentrations of adenosine inhibit, while high 
concentrations stimulate, glutamate release[10]. In fact, previous in vitro experiments indicated a higher 
affinity for adenosine of the A1 compared to the A2A receptor[12]. With weak adenosine release, 
adenosine preferentially stimulates A1 receptors. This preferential stimulation in the A1-A2A receptor 
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heteromer inhibits glutamatergic neurotransmission. Under conditions of stronger adenosine release, A2A 
receptor activation in the A1-A2A receptor heteromer blocks A1 receptor-mediated function, and the 
overall result is a facilitation of the evoked release of glutamate. Thus, the A1-A2A receptor heteromer 
provides a “concentration-dependent switch” mechanism by which low and high concentrations of 
synaptic adenosine produce the opposite effects. 
The A1-A2A receptor heteromer gives a rationale for the existence of heteromers of isoreceptors 
(receptors for the same neurotransmitter) and demonstrates that neurotransmitter heteromers composed of 
isoreceptors with different affinities for their endogenous neurotransmitter and different signaling 
pathways can act as concentration-dependent processors that exert a fine-tune modulation of 
neurotransmission. In this case, we have a neurotransmitter released or formed in the synaptic space that 
acts on synaptically or perisynaptically located heteromers. A weak input results in the stimulation of the 
receptor with the highest affinity for the neurotransmitter, while a strong input results in the additional 
stimulation of the other receptor, with the establishment of the intermolecular cross-talk between both 
receptors an a different neuronal response (Fig. 1). 
 
FIGURE 1. Heteromers of isoreceptors: “concentration-dependent switches”. (a) A weak input 
induces a weak neurotransmitter (NT) release, which activates the receptors with higher affinity for 
the neurotransmitter (NTR1). (b) A stronger input induces a stronger neurotransmitter release, with 
additional activation of the receptors with lower affinity (NTR2), which establishes an 
intermolecular cross-talk between both receptors and induces a different signaling. 
In the case of heteromers of receptors for different neurotransmitters, it is still possible that they are 
localized in the synapse or in the perisynaptic space, where they might be activated by different 
coreleased neurotransmitters (Fig. 2a). The A2A-mGlu5 receptor heteromer constitutes an example, since 
both receptors are mainly localized in the perisynaptic space, adjacent to the postsynaptic density of the 
glutamatergic synapse of the GABAergic enkephalinergic neuron[13]. We have also found evidence for 
the existence of functional interactions between A2A and mGlu5 receptors colocalized in striatal 
glutamatergic terminals[14]. The ability of A2A and mGlu5 receptors to heteromerize was shown in 
transfected mammalian cells and the existence of A2A-mGlu5 receptor heteromers in the striatum was 
supported by coimmunoprecipitation experiments[15]. But these kinds of heteromers, if localized 
extrasynaptically, introduce the possibility of integrating signals conveyed by neurotransmitters released 
by different cells by volume transmission (extrasynaptic diffuse neurotransmission)[13] (Fig. 2b). The 
A2A-D2 receptor heteromer constitutes an example (see below).  
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FIGURE 2. Heteromers of receptors for different neurotransmitters. (a) Neurotransmitter corelease. 
The different units of the receptor heteromer (NT1R and NT2R), which is localized in the synaptic 
or perisynaptic space, are activated by different neurotransmitters (NT1 and NT2) that are coreleased 
in the same synapse; the signaling depends on the intermolecular cross-talk. (b) Volume 
transmission. The different units of the receptor heteromer (NT1R and NT2R), which are localized 
extrasynaptically, are activated by different neurotransmitters released by different cells (NT1 and 
NT2) that reach the heteromer by volume transmission; the signaling depends on the intermolecular 
cross-talk. 
THE ADENOSINE A2A-DOPAMINE D2 AND THE ADENOSINE A2A-GLUTAMATE 
MGLU5 RECEPTOR HETEROMERS: INTEGRATORS OF SIGNALS IN THE 
STRIATAL SPINE MODULE 
Altogether, their different localization (synaptic, extrasynaptic), and the different sources (neurons, glial 
cells) and modes (synaptic and volume transmission) of neurotransmission impinging on them, allow 
receptor heteromers to play a key role in the processing of computations performed by local modules[13]. 
The term “local module” is close to the term “local circuit” defined by Patrizia Goldman-Rakic. “Local 
circuit is that portion of a neuron or neurons that, under given conditions, functions as an independent 
integrative unit”[16]. However, this definition is too general and at the same time too restrictive. It is too 
general because it could include components that are involved in more than one local circuit. It is too 
restrictive because it does not take into account glial cells, which are now well accepted to functionally 
interact with neurons[17]. Furthemore, the word “circuit” implies direct “wired pathways” and 
extrasynaptic neurotransmission (also called “volume transmission”) plays an important role at this level 
of computation. Thus, we have introduced the term “local module” and define it as “the minimal portion 
of one or more neurons and/or one or more glial cells that operates as an independent integrative 
unit”[13].  
We will now review the role of adenosine receptor heteromers in the integration of information in the 
striatal spine module, the most common local module in the striatum. The GABAergic striatal efferent 
neuron constitutes more than 90% of the striatal neuronal population[18]. It is also called medium-sized 
spiny neuron, since it contains a high density of dendritic spines. The GABAergic striatal efferent neuron 
receives two main inputs: glutamatergic afferents from cortical, limbic, and thalamic areas, and 
dopaminergic afferents from the mesencephalon, either the substantia nigra pars reticulata or the ventral 
tegmental area, and both inputs converge in the dendritic spine[18]. The glutamatergic terminal makes 
synaptic contact with the head of the dendritic spine, while the dopaminergic terminal makes synaptic 
contact preferentially with the neck of the dendritic spine[18]. The dendritic spine, the dopaminergic and 
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glutamatergic terminals, and astroglial processes that wrap the glutamatergic synapse constitute the most 
common striatal local module, which we will call striatal spine module[13]. 
This arrangement allows dopamine neurotransmission to regulate glutamatergic neurotransmission, 
but glutamate is not only released synaptically to stimulate intrasynaptic glutamatergic receptors, mostly 
ionotropic receptors. There is also volume transmission of glutamate, which can spill over the synaptic 
cleft and by an amplificatory mechanism that involves the astroglia, stimulates extrasynaptic receptors 
localized both pre- and postsynaptically at the glutamatergic and dopaminergic synapses[13]. Most of 
these extrasynaptic glutamatergic receptors are metabotropic glutamate receptors that modulate glutamate 
and dopamine release[13]. Similarly, dopamine is not only released synaptically, but can also spill over or 
be released by asynaptic varicosities and stimulate extrasynaptic receptors that are located both pre- and 
postsynaptically at both glutamatergic and dopaminergic synapses[13].  
In addition to dopamine, adenosine is a very important modulator of striatal glutamatergic 
neurotransmission. Until recently, it was believed that the main source of extracellular adenosine was a 
paracrine-like formation. Extracellular adenosine would come mostly from intracellular adenosine, the 
concentration of which depends on the breakdown and synthesis of ATP, which is metabolized to AMP 
and, then, by means of 5’nucleotidases, is converted to adenosine, which can be transported to the 
extracelular space by means of equilibrative transporters[19]. However, recent studies suggest that 
astroglia plays a fundamental role in the formation of extracellular adenosine, which affects synaptic 
transmission. Astrocytes express glutamate (mostly metabotropic) and ATP receptors that, when 
activated, induce astrocytes to release glutamate and ATP[20,21]. Astroglial-released ATP can be 
converted to adenosine in the extracellular space by means of ectonucleotidases[22]. Finally, there is an 
increasing number of data that suggest the existence of a synaptic formation of adenosine, i.e., a particular 
synaptic pool of adenosine. In this case, adenosine would come from ATP coreleased with glutamate, 
which is metabolized to adenosine by means of ectonucleotidases[19]. Our finding of presynaptic A1 and 
A2A receptors inside the striatal glutamatergic terminals strongly supports the functional relevance of this 
mechanism[10].  
There are two subtypes of GABAergic striatal efferent neurons: the striatopallidal neuron, also called 
enkephalinergic neuron, which expresses the peptide enkephalin and dopamine and adenosine receptors 
of the D2 and A2A subtypes, and the striatonigral-striatoentopeduncular neuron, also called dynorphinergic 
neuron, which expresses dynorphin and dopamine, and adenosine receptors of the D1 and A1 
subtype[18,19,23]. We found the existence of antagonistic interactions between A2A and D2 receptors that 
modulate the function of the enkephalinergic neuron and antagonistic interactions between A1 and D1 
receptors that modulate the function of the dynorphinergic neuron[19,23]. We were the first to suggest 
that these interactions could provide a new therapeutic strategy for Parkinson’s disease, mostly based on 
the coadministration of A2A receptor antagonists with L-dopa or other dopamine receptor agonists[24]. In 
fact, there is now clinical evidence supporting this hypothesis[25]. We and other groups demonstrated that 
A2A receptors form heteromers with D2 receptors and that A1 receptors form heteromers with D1 receptors 
in transfected cells[26,27,28,29]. Importantly, we and other groups were able to demonstrate the same 
kind of intramembrane A1-D1 and A2A-D2 receptor-receptor interactions (‘biochemical fingerprint”) in 
different transfected cell lines and in the striatum[30,31,32,33,34,35,36,37,38], which demonstrates their 
existence in the brain. 
In the A2A-D2 heteromer, the stimulation of the A2A receptor decreases the binding of dopamine to the 
D2 receptor[30,31,32,33,34,35]. This intramembrane interaction controls neuronal excitability and, 
consequently, neuronal firing and neurotransmitter release (GABA release) by the GABAergic 
enkephalinergic neuron[39,40]. This is most probably related to the ability of D2 receptors to suppress 
Ca2+ currents through L-type VDCCs by a cAMP-PKA-independent and Gq/11-PLC-dependent signaling 
pathway[41]. Thus, stimulation of striatal A2A receptor does not produce a significant effect on its own, 
but it strongly counteracts the depressant effects of D2 receptor stimulation on neuronal firing and 
neurotransmitter release[39,40]. In addition to the intramembrane interaction, a strong antagonistic 
interaction between A2A and D2 receptors has been found at the second messenger level, by which 
stimulation of D2 receptors counteracts the activation of adenylyl-cyclase induced by stimulation of A2A  
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FIGURE 3. Adenosine A2A-dopamine D2 receptor interactions. (a) In the A2A-D2 receptor heteromer, stimulation of the 
A2A receptor decreases the binding of dopamine to the D2 receptor; this intramembrane A2A-D2 interaction seems to involve 
a D2 receptor-Gq/11-PLC signaling pathway. (b) In addition to the intramembrane interaction, in the striatum, a strong 
antagonistic interaction between A2A and D2 receptors has been found at the second messenger level, by which stimulation 
of Gi-coupled D2 receptors counteracts the activation of adenylyl-cyclase (subtype V; AC V) induced by stimulation of A2A 
receptors and, therefore, the consequent activation of the cAMP-PKA-DARPP-32 signaling pathway and induction of the 
expression of different genes, such as c-fos and preproenkephalin; this interaction might not depend on receptor 
heteromerization. 
receptors[27,33]. Stimulation of A2A receptor can potentially stimulate adenylyl-cyclase, with consequent 
activation of cAMP-PKA signaling pathway and induction of the expression of different genes, such as c-
fos and preproenkephalin, by activating the constitutive transcription factor CREB and the MAPK 
pathway[19,23]. Also, A2A receptor-mediated activation of PKA can induce phosphorylation of DARPP-
32[33] and AMPA receptors[42], which plays a crucial role in the initial plastic changes of glutamatergic 
synapses, which includes synaptic recruitment of AMPA receptors[43]. However, under basal conditions, 
stimulation of A2A receptors can poorly activate cAMP-PKA signaling and increase gene expression, due 
to a strong tonic inhibitory effect of endogenous dopamine and D2 receptor stimulation on adenylyl-
cyclase[13,19,42,44,45]. There is, therefore, dissociation between both A2A-D2 receptor interactions. 
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Either costimulation of A2A and D2 receptors results in blockade of the D2 receptor-Gq/11-PLC signaling 
pathway, by means of the intramembrane A2A-D2 interaction, or it results in a blockade of the A2A 
receptor-Gs-olf-cAMP-PKA signaling, by means of the A2A-D2 interaction at the adenylyl-cyclase level 
(Fig. 3). It is possible that when the D2 receptor is not forming heteromers, it couples preferentially to Gi, 
while, when forming heteromers with the A2A receptor, the D2 receptor couples preferentially to Gq/11. 
This would be a similar situation to that recently described for the D1-D2 receptor heteromer[8]. 
Nevertheless, in the D1-D2 receptor heteromer, both receptors couple and signal through Gq/11[8], while in 
the A2A-D2 receptor heteromer, the main function of the A2A receptor seems to be the control of D2 
receptor signaling through Gq/11. In this case, A2A receptor does not couple to Gs/olf, or else there should be 
activation of the cAMP-PKA signaling under basal conditions. 
  
 
FIGURE 4. Metabotropic glutamate mGlu5-adenosine A2A-dopamine D2 receptor heteromers. Under 
basal conditions, in the striatum, stimulation of A2A receptors can poorly activate cAMP-PKA signaling 
and increase gene expression, due to a strong tonic inhibitory effect of endogenous dopamine and D2 
receptor stimulation on adenylyl-cyclase. The mGlu5 receptor heteromerizes and functionally interacts 
with the A2A receptor. By potentiating the effects of A2A receptor on adenylyl-cyclase and MAPK 
activation, mGlu5 receptor coactivation allows the A2A receptor to counteract the inhibitory effect of D2 
receptor. 
Which are, therefore, the conditions that allow the A2A receptor to activate PKA in the GABAergic 
enkephalinergic neuron? One possibility is to decrease dopamine D2 receptor signaling at the same time 
that the A2A receptor is stimulated. We have obtained evidence suggesting that A1 receptor stimulation, 
which is in fact achieved by release of endogenous adenosine, inhibits dopamine release and, therefore, 
enables A2A receptor costimulation to induce a selective activation of gene expression (c-fos, 
preproenkephalin) in the GABAergic enkephalinergic neurons[44,45,46]. Another possibility is to 
potentiate A2A receptor-mediated signaling through Gs-olf. As mentioned before, the Gq/11-coupled mGlu5 
receptor has been shown to physically associate with A2A receptors in transfected cells and in the 
striatum[15]. At the intramembrane level, in rat striatum, stimulation of mGlu5 receptors antagonizes the 
binding of dopamine to the D2 receptor binding, which strongly suggests that it also heteromerizes with 
D2 receptors[47]. Furthermore, stimulation of mGlu5 receptors potentiates the antagonistic effect of A2A 
receptors on D2 receptor binding, suggesting the existence mGlu5-A2A-D2 receptor heteromers[47]. It is, 
therefore, possible that in the mGlu5-A2A-D2 receptor heteromers, D2 receptors predominantly use Gi-
cAMP-PKA signaling (Fig. 4). Furthermore, in transfected HEK cells, we found synergistic interactions 
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between mGlu5 receptor and A2A receptors, by which mGlu5 receptor stimulation potentiates the effects of 
A2A receptor at the MAPK level[15]. In the same cells, stimulation of mGlu5 receptor very strongly 
potentiated c-fos expression induced by A2A receptor stimulation, which was completely counteracted by 
an inhibitor of MAPK activation[15]. Previous studies have shown that activation of Gq/11-coupled 
receptors can amplify adenylyl-cyclase activation induced by Gs-coupled receptor[48]. This was not 
observed in transfected HEK cells[15], but in striatal slices, mGlu5 receptor activation potentiates A2A 
receptor-mediated PKA activation with phosphorylation of DARPP-32[49]. Then, in vivo, costimulation 
of mGlu5 receptors could allow A2A receptors to override the tonic inhibition imposed by D2 receptors and 
induce an increase in gene expression (Fig. 4). In fact, we found that the central coadministration of 
selective A2A and mGlu5 receptor agonists induces an increase in the striatal expression of c-fos, while no 
significant effect was obtained when they were administered alone[15]. 
In different behavioral models, mGlu5 receptor agonists and antagonists produce similar effects to A2A 
receptor agonists and antagonists, respectively, including selective modulation of D2 receptor-mediated 
effects. A selective mGlu5 receptor agonist preferentially inhibits motor activation induced by D2 receptor 
agonists[47], whereas mGlu5 receptor antagonists counteract the effects of D2 receptor antagonists[50]. 
Furthermore, A2A and mGlu5 receptor agonists and A2A and mGlu5 receptor antagonists also show 
synergistic effects at the behavioral level[15,47,51,52]. A2A-D2-mGlu5 receptor interactions provide the 
rationale for the coapplication of A2A and mGlu5 receptor antagonists in Parkinson’s disease[51,52]. 
How do the pre- and postsynaptic heteromers that contain A2A receptors modulate glutamatergic 
neurotransmission in the striatal spines of the enkephalinergic neurons? Under weak cortico-limbic input, 
we have a preferential A1 receptor-mediated modulation in the A1-A2A receptor heteromer at the 
presynaptic side, and a preferential D2 receptor-mediated modulation in the A2A-D2, and possibly A2A-D2-
mGlu5 heteromers, in the postsynaptic side. This provides weak glutamatergic neurotransmission, weak 
neuronal excitability, and weak gene expression and plastic changes. Under strong cortico-limbic input, 
we have a strong release of glutamate and formation of synaptic adenosine, which stimulates presynaptic 
A2A receptors in the A1-A2A receptor heteromer, which shuts down A1 receptor signaling and promotes 
further glutamate release. Second, synaptic glutamate and adenosine can overflow from the synaptic 
space and activate A2A and mGlu5 receptors forming heteromers in the perisynaptic postsynaptic side. 
Thus, we have a strong activation of the A2A and mGlu5 receptors in the A2A-D2 and possibly A2A-D2-
mGlu5 receptor heteromer, which shuts down D2 receptor signaling and increases neuronal excitability 
and also allows gene expression, protein synthesis and synaptic plasticity. As mentioned above, we 
should also consider a possible role of A1 receptor stimulation in dopaminergic nerve terminals by 
endogenous adenosine, which would decrease dopamine release and contribute to the decreased D2 
receptor signaling. 
Thus, stimulation A2A receptors in the pre- and postsynaptic A2A receptor-containing heteromers 
seems to play a key role in the functional changes of the glutamatergic synapses of the enkephalinergic 
neuron during conditions of strong cortico-limbic input. In agreement, we have recently shown that A2A 
receptor blockade completely counteracts MAPK activation (phosphorylation of ERK1/2) in the 
GABAergic enkephalinergic neurons induced by cortical electrical stimulation[53].  
This can have implications for the treatment of drug addiction: The glutamatergic projections from 
the prefrontal cortex to the nucleus accumbens (particularly the nucleus acumbens core) seem to play a 
key role in relapse to drugs of addiction[54]. Given the key role of the A2A receptors of pre- and 
postsynaptic heteromers in the glutamatergic synapses of the GABAergic enkephalinergic neurons, A2A 
receptor antagonists could provide a treatment for relapse[55].  
CONCLUSIONS 
Reviewing the functional role of adenosine receptor heteromers allowed us to discover the functional 
relevance of neurotransmitter receptor heteromers at different levels of analysis of brain function. First, at 
the receptor level, a receptor unit in the heteromer can display several biochemical properties, which can 
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be dependent on costimulation of the other unit (or units, in case of receptor heteromultimers). In this 
case, the neurotransmitter receptor heteromer acts as a “processor” of computations that modulate cell 
signaling. Second, this process of information might be involved in the modulation of cell signaling 
critically involved in the control of pre- and postsynaptic neurotransmission. Finally, at a higher level of 
analysis, neurotransmitter receptor heteromers play an important role in the computation of information 
performed by “local modules”. This does not only depend on their intrinsic ability to process information, 
but on their intra- and extrasynaptic localization, which allows them to integrate signals coming from 
different sources (neurons, glia) and using different modes (synaptic and volume transmission) of 
neurotransmission. Many questions about receptor heteromers remain to be answered. For instance, we 
still need to determine the detailed molecular mechanisms by which heteromerization changes the 
biochemical characteristics of a receptor or by which stimulation of one receptor in the heteromer leads to 
the allosteric modification of the adjacent receptor that changes its functional characteristics. Also, in this 
review, we have been focusing on adenosine receptor heteromers, and adenosine does not only activate 
receptor heteromers, but also adenosine receptor homomers, which should obviously be taken into 
account when trying to fully understand the functional role of adenosine in a particular local module. In 
any case, the realization of the functional relevance of neurotransmitter receptor heteromers can have 
important implications for the treatment of neuropsychiatric disorders and drug addiction. 
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